Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.5 / 5 stars · 46/91 Roast Me

Celldex Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Celldex Therapeutics, Inc. (CLDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2022-05-05

  • Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-09-30 was 0.00%.
  • Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-06-30 was 0.00%.
  • Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month
2022-03-310.00%
10-Q · filed 2022-05-05
2021-09-300.00%
10-Q · filed 2021-11-09
0.00%
10-Q · filed 2021-11-09
2021-06-300.00%
10-Q · filed 2021-08-05
0.00%
10-Q · filed 2021-08-05
2021-03-310.00%
10-Q · filed 2022-05-05
2020-09-300.00%
10-Q · filed 2021-11-09
0.00%
10-Q · filed 2021-11-09
2020-06-300.00%
10-Q · filed 2021-08-05
0.00%
10-Q · filed 2021-08-05
2020-03-310.00%
10-Q · filed 2021-05-06
2019-09-300.00%
10-Q · filed 2020-11-05
0.00%
10-Q · filed 2020-11-05
2019-06-300.00%
10-Q · filed 2020-08-06
0.00%
10-Q · filed 2020-08-06
2019-03-310.00%
10-Q · filed 2020-05-06
2018-09-300.00%
10-Q · filed 2019-11-12
0.00%
10-Q · filed 2019-11-12
2018-06-300.00%
10-Q · filed 2019-08-07
0.00%
10-Q · filed 2019-08-07
2018-03-310.00%
10-Q · filed 2019-05-07
2017-09-300.00%
10-Q · filed 2018-11-07
0.00%
10-Q · filed 2018-11-07
2017-06-300.00%
10-Q · filed 2018-08-08
0.00%
10-Q · filed 2018-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93